tetano
Editor, Senior Moderator
Dis Model Mech
. 2020 Sep 1;13(9):dmm046581.
doi: 10.1242/dmm.046581.
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
Sarah R Leist[SUP] 1 [/SUP], Alexandra Sch?fer[SUP] 1 [/SUP], David R Martinez[SUP] 2 [/SUP]
Affiliations
Abstract
The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic.
Keywords: Animal models; Cell models; MERS-CoV; SARS-CoV; SARS-CoV-2.
. 2020 Sep 1;13(9):dmm046581.
doi: 10.1242/dmm.046581.
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
Sarah R Leist[SUP] 1 [/SUP], Alexandra Sch?fer[SUP] 1 [/SUP], David R Martinez[SUP] 2 [/SUP]
Affiliations
- PMID: 32887790
- DOI: 10.1242/dmm.046581
Abstract
The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic.
Keywords: Animal models; Cell models; MERS-CoV; SARS-CoV; SARS-CoV-2.